286 related articles for article (PubMed ID: 26666647)
1. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
4. Biology of ovarian cancer and trabectedin mechanism of action.
Ray-Coquard I
Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin mechanism of action and platinum resistance: molecular rationale.
Ray-Coquard I
Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin for the treatment of breast cancer.
D'Incalci M; Zambelli A
Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
[TBL] [Abstract][Full Text] [Related]
8. A review of trabectedin (ET-743): a unique mechanism of action.
D'Incalci M; Galmarini CM
Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
D'Incalci M; Badri N; Galmarini CM; Allavena P
Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin mechanism of action: what's new?
D'Incalci M
Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
14. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
15. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
[TBL] [Abstract][Full Text] [Related]
16. Role of homologous recombination in trabectedin-induced DNA damage.
Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G
Eur J Cancer; 2008 Mar; 44(4):609-18. PubMed ID: 18243687
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
Herrero AB; Martín-Castellanos C; Marco E; Gago F; Moreno S
Cancer Res; 2006 Aug; 66(16):8155-62. PubMed ID: 16912194
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.
Harnicek D; Kampmann E; Lauber K; Hennel R; Cardoso Martins AS; Guo Y; Belka C; Mörtl S; Gallmeier E; Kanaar R; Mansmann U; Hucl T; Lindner LH; Hiddemann W; Issels RD
Int J Cancer; 2016 Jul; 139(2):467-79. PubMed ID: 26933761
[TBL] [Abstract][Full Text] [Related]
19. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
Aune GJ; Takagi K; Sordet O; Guirouilh-Barbat J; Antony S; Bohr VA; Pommier Y
Clin Cancer Res; 2008 Oct; 14(20):6449-55. PubMed ID: 18927284
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
